Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes

Arthritis and Rheumatism

Volumn 41, Issue 8, 1998, Pages 1420-1427

  Reverter, Joan Carles ^a   Tàssies, Dolors ^a   Font, Josep ^a   Khamashta, Munther A ^b   Ichikawa, Kenji ^c   Cervera, Ricard ^a   Escolar, Ginés ^a   Hughes, Graham R V ^b   Ingelmo, Miguel ^a   Ordinas, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; MONOCLONAL ANTIBODY; THROMBOPLASTIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULIN M; MIDDLE AGED; MONOCYTES; THROMBOPLASTIN;

EID: 0031876263     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199808)41:8<1420::AID-ART11>3.0.CO;2-U     Document Type: Article

References (50)

1. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. BMJ 1983;287:1021-3.
2. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444-54.
3. Schorer AE, Wickham NW, Watson KV. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 1989;71: 399-407.
4. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426-32.
5. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101-7.
6. Reverter JC, Tàssies D, Escolar G, Font J, López-Soto A, Ingelmo M, et al. Effect of plasma from patients with primary antiphospholipid syndrome in platelet function in a collagen rich perfusion system. Thromb Haemost 1995;13:132-7.
7. Reverter JC, Tàssies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with the antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996;16:1319-26.
8. Martini F, Farsi A, Gori AM, Boddi M, Fedi S, Domeneghetti MP, et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 1996;5:206-11.
9. Rustin MHA, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988;90: 744-8.
10. Oosting JD, Derksen RHWM, Blokzijl L, Sixma JJ, De Groot PG. Antiphospholipid positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis system. Thromb Haemost 1992;68:278-84.
11. Barstad RM, Hamers MJAG, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor Vila-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol 1995;15:11-6.
12. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168:206-10.
13. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero G, et al. Effect of human IgG antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994;71:670-4.
14. Branch DW, Dudley DJ, Mitchell MD, Crightari KA, Abott JM, Hammond EH, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163:210-6.
15. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991;88:3069-73.
16. Bakimer R, Fishman P, Blank M, Srednc B, Djaidetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest 1992;89:1558-63.
17. Gharavi AE. Antiphospholipid syndrome in murine lupus. In: Harris EN, Exner T, Asherson RA, Hughes GRV, editors. Phospholipid binding antibodies. Boca Raton (FL): CRC Press; 1991. p. 403-16.
18. Smith HR, Hansen RL, Rose R, Canoso RT. Autoimmune MRL-lrp/lrp mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990;17:911-5.
19. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, et al. Anticardiolipin antibodies in NZW x BXSB F1 mice: a model of antiphospholipid syndrome. J Immunol 1992;149: 1063-8.
20. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
21. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165:1272-7.
22. Ruíz-Argüelles G, Ruíz-Argüelles A, Lobato-Mendizabal E, Díaz-Gómez F, Pacheco-Pantoja E, Drenkar C, et al. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. Am J Hematol 1991;37:9-13.
23. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 1991;77:354-9.
24. Parke AL, Weinstein RE, Bona RD, Maier DB, Walker FJ. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med 1992;93:49-56.
25. Ruíz-Argüelles G, Ruíz-Argüelles A, Alarcón-Segovia D, Drenkar C, Villa A, Cabiedes J, et al. Natural anticoagulants in systemic lupus erythematosus: deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 1991;18:552-8.
26. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
27. Escolar G, Font J, Reverter JC, López-Soto A, Garrido M, Cervera R, et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation: studies in a perfusion system. Arterioscler Thromb 1992; 12:196-200.
28. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-32.
29. 2-glycoprotein I. Proc Natl Acad Sci U S A 1990;87:4120-4.
30. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breida-Vrieasman PJC, et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
31. 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995;155:1629-36.
32. 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994;37:1453-61.
33. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
34. Cervera R, Font J, López-Soto A, Casals F, Pallarés L, Bové A, et al. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis 1990;49:109-13.
35. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
36. 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Br J Rheumatol 1997;36:113-6.
37. Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantelli P, et al. Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol 1985;17:155-62.
38. Baumgartner HR, Muggli R. Platelet adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Gordon JL, editor. Platelets in biology and pathology. Amsterdam: North-Holland Publishing Company; 1976. p. 23-60.
39. Baumgartner HR. Platelet interactions with collagen fibrils in flowing blood. I. Reaction of human platelets with α-chymotrypsin digested subendothelium. Thromb Haemost 1977;37:1-16.
40. Escolar G, Bastida E, Castillo R, Ordinas A. Development of a computer program to analyze the parameters of platelet-vessel wall interaction. Haemostasis 1986;16:8-14.
41. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964;20:482-91.
42. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988;47:849-54.
43. Arfors L, Vesterqvist O, Johnsson H, Green K. Increased thromboxane formation in patients with antiphospholipid syndrome. Eur J Clin Invest 1990;20:607-12.
44. Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, et al. Reduction of annexin V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994;171: 1566-72.
45. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997;54:209-13.
46. McCrae KR, De Michele AM, Pandhi P, Balsai MJ, Samuels P, Graham C, et al. Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 1993;82:2730-4.
47. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288), and a region recognized by anticardiolipin antibodies. J Immunol 1994;152:653-9.
48. 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-61.
49. Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-41.
50. Vermylen J, Hoylaerts MF, Arnout J. Antibody mediated thrombosis. Thromb Haemost 1997;78:420-6.